brepocitinib · Lisraya
Small molecule
Also known as PF-06700841
Evidence outlook
Approved: Dermatomyositis (label: adults), Idiopathic Inflammatory Myopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Latest reported trial: VALOR (NCT05437263) · Phase 3 · met primary endpoint · grade pending
Also in development:Non-Infectious Uveitis · Phase 3Cutaneous Sarcoidosis · Phase 2/3Lichen Planopilaris · Phase 2/3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
VALOR NCT05437263 · Dermatomyositis Registry: NCT05437263 | 3 | Total Improvement Score (TIS) at Week 52 (52 weeks) 2025-07-17 | Week-52 Total Improvement Score 46.5 (30 mg), 37.5 (15 mg), 31.2 (placebo); 30 mg beat placebo by 15.3 points (P<0.001), 15 mg did not (difference 6.3, CI -2.4 to 14.9). | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1 (1)
What this study did
Competitive landscape
Other TYK2/JAK1 drugs
Soficitinib (ICP-332), BHV-8000, TDM-180935, Girocitinib. Compare all 5 TYK2/JAK1 drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Dermatomyositis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Brepocitinib (Lisraya): this drug | Approved | Small molecule | TYK2/JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| PF-06823859 | Phase 3 | Monoclonal antibody | Interferon beta (IFN-beta) | not yet graded | No reviewed efficacy summary in this indication | |
| BHV-8000 | Phase 2/3(overall) | Small molecule | TYK2/JAK1 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| TDM-180935 | Phase 2(overall) | Small molecule | TYK2/JAK1 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Descartes-08 | Phase 1/2 | Cell therapy | BCMA (B-cell maturation antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadefrecitinib | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lisraya (brepocitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent